Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 13/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.41 |
| ▸ | BACE1 | P56817 | 3/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.36 |
| ▸ | F11 | P03951 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29410000 | 1.00 | LPL (0.41) | LPLLIPGBACE1ROCK1CA1 | |
| SCHEMBL29409998 | 1.00 | LPL (0.41) | LPLLIPGBACE1ROCK1CA1 | |
| SCHEMBL2010946 | 0.91 | LPL (0.39) | LPLLIPGBACE1ROCK1CA1 | |
| SCHEMBL2225037 | 0.89 | BACE1 (0.43) | LPLLIPGBACE1ROCK1CA1 | |
| SCHEMBL31394725 | 0.84 | LPL (0.41) | LPLLIPGBACE1ROCK1CA1 | |
| SCHEMBL2012175 | 0.81 | LPL (0.44) | LPLLIPGBACE1CA1CA2 | |
| SCHEMBL29502333 | 0.81 | LPL (0.47) | LPLLIPGBACE1ROCK1CA1 | |
| SCHEMBL16639375 | 0.81 | LPL (0.47) | LPLLIPGBACE1ROCK1CA1 | |
| SCHEMBL24335646 | 0.79 | BACE1 (0.44) | LPLLIPGBACE1ROCK1CA1 | |
| SCHEMBL2016481 | 0.79 | LPL (0.40) | LPLLIPGBACE1ROCK1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4289480-A2 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | F. Hoffmann-La Roche AG (CH) | 2023-12-13 | — | — | EP | disclosed |
| EP-4289480-A2 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | F. Hoffmann-La Roche AG (CH) | 2023-12-13 | — | — | EP | disclosed |
| CN-115215923-A | Macrocyclic broad spectrum antibiotics | 豪夫迈·罗氏有限公司 | 2022-10-21 | — | — | CN | disclosed |
| CN-114007605-B | Macrocyclic broad spectrum antibiotics | 豪夫迈·罗氏有限公司 | 2022-07-15 | — | — | CN | disclosed |
| US-20220135528-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | GENENTECH, INC. (US AND US TERRITORIES) | 2022-05-05 | — | — | US | disclosed |
| US-20220135528-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | GENENTECH, INC. (US AND US TERRITORIES) | 2022-05-05 | — | — | US | disclosed |
| EP-3968983-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | F. Hoffmann-La Roche AG (CH) | 2022-03-23 | — | — | EP | disclosed |
| CN-114007605-A | Macrocyclic broad spectrum antibiotics | 豪夫迈·罗氏有限公司 | 2022-02-01 | — | — | CN | disclosed |
| US-11208387-B2 | Macrocyclic broad spectrum antibiotics | GENENTECH, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-11208387-B2 | Macrocyclic broad spectrum antibiotics | GENENTECH, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| WO-2020243155-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | GENENTECH, INC. (US) | 2020-12-03 | — | — | WO | disclosed |
| US-9062015-B2 | Inhibitors of sphingosine kinase | MERCK PATENT GMBH (DE) | 2015-06-23 | — | — | US | disclosed |
| US-9062015-B2 | Inhibitors of sphingosine kinase | MERCK PATENT GMBH (DE) | 2015-06-23 | — | — | US | disclosed |
| US-9062015-B2 | Inhibitors of sphingosine kinase | MERCK PATENT GMBH (DE) | 2015-06-23 | — | — | US | disclosed |
| EP-2513057-B1 | SPHINGOSINE KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2013-09-04 | — | — | EP | disclosed |
| EP-2513057-A1 | SPHINGOSINE KINASE INHIBITORS | Merck Patent GmbH (DE) | 2012-10-24 | — | — | EP | disclosed |
| US-20120252789-A1 | INHIBITORS OF SPHINGOSINE KINASE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-10-04 | — | — | US | disclosed |
| US-20120252789-A1 | INHIBITORS OF SPHINGOSINE KINASE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-10-04 | — | — | US | disclosed |
| US-20120252789-A1 | INHIBITORS OF SPHINGOSINE KINASE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-10-04 | — | — | US | disclosed |
| WO-2011072791-A1 | SPHINGOSINE KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135528-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, CLPP, PEPD | LPL 190/4885LIPG 1392/4885BACE1 131/4885 |
| US-20120252789-A1 | INHIBITORS OF SPHINGOSINE KINASE | SPHK1, SPHK2, S1PR3 | LPL 2372/4885LIPG 1527/4885BACE1 374/4885 |
| US-11208387-B2 | Macrocyclic broad spectrum antibiotics | MRPL21, CLPP, PEPD | LPL 190/4885LIPG 1392/4885BACE1 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.